Financial Results for FY2017
(Year ended March 31, 2018)

from the beginning

Financial Results for FY2017 (Year ended March 31, 2018)

• Disclaimer Regarding Forward-looking Statements

Financial Results for FY2017

• FY2017 Major Topics

• Financial Results for FY2017 (JGAAP)

• IFRS (Full Basis) - JGAAP Comparison (FY2017)

• Financial Results for FY2017 (Full Basis)

• Adjustments to Core Operating Profit

• Financial Results for FY2017 (Core Basis)

• Segment Information (Core Basis)

• Revenue of Major Products in Japan

• Revenue of Major Products in North America & China

The Third Mid-term Business Plan in Review (FY2013 to FY2017)

• Vision and The Third Mid-term Business Plan

• The Third Mid-term Business Plan: What We Have Achieved (1)

• The Third Mid-term Business Plan: What We Have Achieved (2)

• Trend of Business Results

Activities in FY2018

• Japan Business

• North America and China Business

• R&D (1)

• R&D (2)

• Corporate Governance and others

Financial Forecasts for FY2018

• Financial Forecasts for FY2018 (Core Basis)

• Segment Information (Core Basis)

• Revenue of Major Products in Japan

@25

• Revenue of Major Products in North America & China

@25

@27

• Investment Strategies / Dividend Policy

Research and Development

• R&D: Area Strategy

• Development pipeline (as of May 2018)

• Product Launch Target (as of May 2018)

Appendices

• IFRS (Full Basis) - JGAAP Comparison (FY2016)

• Profit before Taxes and Profit Attributable to Owners of the Parent

• Financial Position / Cash Flows

• New Products Profile

• Regenerative Medicine/Cell Therapy Business Plan (as of May 2018)

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8